Carole Ho serves as Executive at Denali Therapeutics Inc., where they oversee executive responsibilities. Since joining the company, Carole Ho has executed 158 insider transactions totaling $12.9M, demonstrating a bearish approach to their equity position. Their most recent transaction on Dec 3, 2018 involved selling 400 shares valued at $7.7K.
Carole Ho currently holds 216,585 shares of Denali Therapeutics Inc. (DNLI), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Carole Ho has been a net seller of DNLI stock. They have purchased $0 and sold $12.9M worth of shares.
Carole Ho's most recent insider trade was on Dec 3, 2018, when they sold 400 shares at $19.16 per share.
Get notified when new Form 4 filings are submitted
| $18.43 |
| Discretionary |
| Nov 15, 2018 | DNLI | $64.6K | Option Exercise | 12,235 | $5.28 | Discretionary |
| Nov 15, 2018 | DNLI | $316.2K | Sale | 17,500 | $18.07 | Discretionary |
| Nov 15, 2018 | DNLI | $316.2K | Sale | 17,500 | $18.07 | Discretionary |
| Oct 1, 2018 | DNLI | $380.1K | Sale | 17,500 | $21.72 | Discretionary |
| Sep 4, 2018 | DNLI | $333.4K | Sale | 17,500 | $19.05 | Discretionary |
| Aug 29, 2018 | DNLI | $315.7K | Sale | 17,500 | $18.04 | Discretionary |